A Coordinated Six-Agent Protocol for Improved Anti-Tumor Immunity

The Immune Logic of Cancer

Cancer is not really a problem of cell division. Genetically abnormal cells appear in healthy tissue every day, and a working immune system clears them before they can organize into tumors. Cancer happens when that clearance fails. Every tumor that grows to clinical disease has, by that fact alone, succeeded at evading the immune system. It does so through a coordinated set of strategies. It hides its antigens behind metabolic and oxidative shields. It suppresses the immune cells that infiltrate it. It recruits macrophages and regulatory T cells that protect rather than attack it. It releases immunosuppressive debris into the surrounding tissue. And it exploits checkpoint pathways that suppress any T cell response that begins to form.

Restoring anti-tumor immunity means countering each of these evasion strategies. A single agent can address one step in the chain by which the immune system recognizes and destroys cancer cells, but no single agent addresses them all. A tumor that has been made antigenically visible will not be destroyed if the responding T cells are exhausted. A trained innate immune system will not mount a coordinated attack if dendritic cells are dysfunctional. A well-armed adaptive immune system will be defeated if the tumor microenvironment keeps releasing chromatin debris that activates checkpoints, or if its acidic pH paralyzes the T cells that arrive to do the killing. The immune destruction of cancer is a multi-step process, and any strategy aimed at restoring it must act on multiple steps simultaneously.

The six-agent protocol described here is built around that logic. Each agent addresses a specific function in the chain. None is sufficient by itself. Together, they form a coordinated strategy to restore the immune surveillance that cancer has defeated.

The Cancer-Immunity Cycle

Tumor immunologists describe the immune destruction of cancer as a sequential cycle. Cancer cells must first die in a way that releases their antigens into the surrounding tissue, ideally accompanied by danger signals that recruit and activate antigen-presenting cells. Dendritic cells then capture those antigens, mature, and present them in regional lymph nodes. Naive T cells get primed against tumor-specific neoantigens, traffic to the tumor, infiltrate it, recognize the cancer cells they encounter, and kill them. Each killed cell releases more antigens that feed the next round of the cycle.

This cycle can stall at any step, and in most patients with progressive cancer, it stalls at several steps at once. The six-agent protocol is organized to act on each stage. The agents are presented below in the order of steps, beginning with antigen release and ending with the durable maintenance of cytotoxic effector function.

The Six Functional Roles Within the Protocol

1. High-ozonide oil: Antigen release through immunogenic cell death

Anti-tumor immunity begins with cancer cells dying in a way the immune system can interpret. Cells dying by routine apoptosis are quietly cleared and produce no immune response. Cells dying under mitochondrial stress, oxidative damage, and intrinsic apoptotic activation produce immunogenic cell death, characterized by exposure of calreticulin on the cell surface, release of HMGB1 and ATP into the extracellular space, and liberation of tumor antigens, including the unique mutated neoantigens that distinguish each cancer from healthy tissue. High-ozonide oil (HOO) is the agent in this protocol that drives this kind of cell death. Its lipophilic ozonides penetrate cancer cells, oxidize the cardiolipin of structurally compromised tumor mitochondria, and trigger intrinsic apoptosis with a mitochondrial stress signature that produces an immunogenic profile. The Izzotti 2022 study in Cancers documented apoptotic activation by Annexin V flow cytometry, demonstrated mitochondrial calcium release by fluorescence microscopy, and confirmed selective sparing of healthy cells whose mitochondria retain a properly assembled cardiolipin bilayer. The result is a sustained release of tumor antigens alongside the danger signals that downstream immune steps require.

2. Microdosed resveratrol-copper: Clearance of immunosuppressive debris

Cancer cell death, however produced, releases more than just antigens. It also releases cell-free chromatin particles, fragments of DNA still wrapped around histones, that are biologically active and harmful to the immune response that the antigen release is meant to provoke. Indraneel Mittra’s group at Tata Memorial Centre has shown that these particles enter healthy bystander cells, integrate into their genomes, generate DNA breaks and inflammation, and directly activate immune checkpoints on T cells, including PD-1, CTLA-4, LAG-3, TIM-3, and NKG2A. Without continuous clearance, chromatin debris from any source of tumor cell killing, whether HOO-induced apoptosis, chemotherapy, radiation, or natural turnover, will switch off the very T cell responses the protocol is trying to mobilize. Microdosed resveratrol-copper performs that clearance. The microdose reduces cupric copper to cuprous copper, which generates targeted oxygen radicals via a Fenton-like reaction that degrades the DNA component of these particles, rendering them biologically inactive. The result is a tumor microenvironment in which cell death produces antigens for immune recognition without producing the checkpoint-activating debris that would defeat that recognition.

3. Alkalinization therapy: Restoring the immune microenvironment

Even when antigens are released and chromatin debris is cleared, the immune system still has to do its work somewhere, and that somewhere is the tumor microenvironment. In most solid tumors, glycolytic metabolism and poor perfusion drive extracellular pH down to about 6.5 to 6.9, well below the 7.3 to 7.4 range required for normal immune function. Boedtkjer and Pedersen’s 2020 review in the Annual Review of Physiology described this acidic environment as a global driver of cancer progression, multidrug resistance, and immune evasion. T cells inside it lose the ability to release cytotoxic granules, produce cytokines, and proliferate. Natural killer cells become functionally anergic. Dendritic cells lose their capacity for antigen presentation. Regulatory T cells and myeloid-derived suppressor cells, by contrast, thrive in acidic conditions, adding more immunosuppression.

Alkalinization raises extracellular pH back toward physiologic levels through dietary modification, oral sodium bicarbonate, and related strategies. Pilon-Thomas and colleagues showed in 2016 in Cancer Research that neutralizing tumor acidity with oral bicarbonate restored T cell function in the tumor microenvironment and significantly improved responses to anti-CTLA-4 and anti-PD-1 antibodies, as well as adoptive T cell therapy, in mouse models of melanoma and pancreatic cancer. Calcinotto and colleagues showed that alkalinization reverses anergy in human and murine tumor-infiltrating T lymphocytes, restoring the cytotoxic capacity that acidity had silenced. Within this protocol, alkalinization is the environmental enabler, letting every other agent do its work where it matters most: inside the tumor itself.

The aim is not to alter blood pH, which is held in a narrow range by hemoglobin, plasma proteins, and the bicarbonate buffer. Tumor interstitial fluid has a dramatically lower buffering capacity, so oral bicarbonate preferentially accumulates in poorly perfused regions within tumors, producing localized neutralization without meaningfully altering systemic pH.

4. Beta-glucans: Innate immune training

The danger signals released by immunogenic cell death must be recognized by competent innate immune cells, principally macrophages, neutrophils, and natural killer cells. In most cancer patients, those cells are present in adequate numbers but functionally muted, whether due to age, chronic disease, or immunosuppressive cytokines produced by the tumor itself. Beta-glucans, particularly the beta-1,3/1,6-glucans from yeast and from the mushroom Trametes versicolor, train these cells through Dectin-1 engagement and CR3 priming. The training works at the epigenetic level: it reprograms bone marrow progenitors so that mature innate cells produce more cancer-fighting cytokines, respond more quickly to threats, and maintain that heightened state for weeks to months. The 2020 Cell paper by Kalafati and colleagues from Mihai Netea’s group showed that this trained innate immunity directly suppresses tumor growth in animal models, and decades of Japanese clinical experience with PSK as a chemotherapy adjuvant indicate that this effect translates into better survival in colorectal and gastric cancer. Within this protocol, beta-glucans ensure that innate immune cells responding to antigens released by HOO are functionally capable of mounting a vigorous response.

5. Thymosin alpha-1: Adaptive immune command

Innate immunity alone cannot eradicate established cancer. Durable tumor control requires an adaptive T cell response targeted to tumor-specific neoantigens, and that in turn requires functional dendritic cells to present them, a diverse T cell repertoire to recognize them, and polarization of tumor-associated macrophages toward the M1 phenotype that supports rather than suppresses T cell activity. Thymosin alpha-1 commands this adaptive arm. It matures dendritic cells and increases their expression of MHC class II, CD80, and CD86, the surface markers required for productive T cell activation. It supports thymic maturation of new T cells, broadening the repertoire available to recognize tumor neoantigens. And as Wei and colleagues documented in their 2022 Cancer Research paper, it actively reverses M2 polarization of tumor-associated macrophages, converting them from tumor-supporting to tumor-fighting cells.

The clinical evidence base for thymosin alpha-1 in cancer spans more than 30 trials and over 11,000 patients, with notable survival benefits in non-small cell lung cancer and hepatocellular carcinoma. Despite this track record, it has not yet received FDA approval in the United States, where it currently holds orphan drug designation and is accessed through investigational protocols or compounding pharmacies. It is approved in more than 35 countries, including China, Italy, and Russia, where its synthetic form, thymalfasin, is marketed as Zadaxin and used as an adjuvant cancer therapy and for chronic hepatitis B and C.

6. Low-dose naltrexone: Sustained response and growth restraint

An anti-tumor immune response, once established, has to be sustained. Tumors evolve, T cells exhaust, and natural killer cell cytotoxicity fluctuates. Low-dose naltrexone supports the protocol along three axes that all serve sustained effector function. By transiently blocking opioid receptors at night, it triggers a compensatory rise in opioid growth factor and beta-endorphin that persists through the day. The elevated opioid growth factor binds the OGFr receptor on cancer cells and activates the p16 and p21 cell-cycle brakes, slowing tumor proliferation and buying time for the immune response to gain ground. Elevated beta-endorphin levels enhance natural killer cell cytotoxicity, directly amplifying the killing of cancer cells. The rest of the protocol has been marked for destruction. And LDN’s effects on TLR4 signaling reduce the chronic inflammation that promotes T cell exhaustion, helping preserve the cytotoxic T cell response over the months and years required for durable disease control.

How the Six Functions Reinforce Each Other

The protocol is more than the sum of its parts because each function depends on and amplifies the others. The reinforcements are multilateral rather than linear. A few patterns are worth describing.

The macrophage repolarization convergence

Four of the six agents converge on the same macrophage polarization shift from opposite directions. HOO disrupts the reactive oxygen species signaling that maintains M2 dominance, partially dismantling the tumor-supporting state. Beta-glucans, through engagement of Dectin-1, actively train macrophages toward the M1 cancer-fighting state. Thymosin alpha-1, through its effects on macrophage transcription, directly repolarizes M2 macrophages back to M1. Alkalinization removes the acidic milieu that locks macrophages into M2 in the first place, preventing them from drifting back as the others do their work. The combined effect is greater than any of the four would produce alone, and it addresses arguably the single most important immunosuppressive feature of solid tumors.

The antigen presentation chain

Releasing tumor antigens is only the first step in mobilizing an adaptive response. The antigens have to survive long enough to be captured by competent dendritic cells; those cells have to be functional enough to mature and migrate; and the T cells they encounter in regional lymph nodes have to be diverse enough to recognize tumor-specific neoantigens. The protocol acts on every link. HOO releases the antigens. R-Cu protects the resulting immune response from being shut down by chromatin debris. Alkalinization restores the dendritic cell antigen presentation that acidity had silenced. Beta-glucans prime macrophages and natural killer cells involved in early antigen processing. Thymosin alpha-1 matures the dendritic cells and broadens the T cell repertoire that recognizes them. Removing any one of these steps would break the chain at exactly the point where single-agent immune therapies typically fail.

The cytotoxic effector loop

The cells that ultimately kill cancer are cytotoxic CD8 T cells and natural killer cells. Their effectiveness depends on their number and activation state, as well as the visibility of the targets they are sent to attack. Four of the six agents amplify cytotoxic effector function. Beta-glucans prime natural killer cells and enhance their ability to kill antibody-tagged tumor cells. Thymosin alpha-1 restores exhausted CD8 T cells and enhances cytotoxic granule release. LDN elevates beta-endorphin signaling, further enhancing natural killer cytotoxicity. Alkalinization restores T cell metabolism, granzyme release, and cytotoxic synapse formation that the acidic tumor microenvironment had paralyzed. The targets these effectors recognize are made more visible by HOO, which, through immunogenic cell death, exposes the calreticulin and stress signals that natural killer cells preferentially attack. The result is a coordinated increase in both effector capacity and target visibility.

The exhaustion prevention triangle

Long-term tumor control fails most often not because the immune system never mounted a response, but because the response it mounted became exhausted. Exhaustion is driven by checkpoint activation, by chronic inflammatory signaling, and by the metabolic stress of sustained T cell activity. The protocol addresses each driver. R-Cu degrades the chromatin debris that activates checkpoints. LDN reduces TLR4-mediated inflammatory signaling and lowers exhaustion markers. Thymosin alpha-1 stabilizes T-cell function and counteracts regulatory T-cell suppression. Together, they protect the cytotoxic T cell population that HOO and beta-glucans have helped to generate, allowing the response to persist over the months and years required for durable disease control.

Why a Coordinated Six-Agent Strategy

The cancer-immunity cycle has multiple steps because the immune destruction of cancer is itself a multi-step process. Each step has its own bottlenecks, and a tumor that has progressed to clinical disease has typically defeated several at once. Single-agent immune therapies reopen one step at a time, which is why most produce response rates in only a minority of patients and why those responses often prove temporary. A protocol that reopens six steps simultaneously operates on a different mechanistic basis. It does not depend on any one step being the dominant bottleneck for any individual patient. It addresses the full chain by which immune surveillance has failed, with six agents that share an exceptional safety profile, decades of individual clinical use, and complementary rather than redundant mechanisms.

The combination has not been tested in a formal clinical trial. The synergies described above are biologically grounded and consistent with what is known about each individual agent, but they are theoretical until proven in patients. What is not theoretical is the safety record of each agent individually, the mechanistic coherence of the combination, and the strength of the evidence that anti-tumor immunity, when fully restored, can control and sometimes eliminate even advanced disease. The protocol is intended to complement, not replace, conventional cancer treatment, and every patient considering it should do so in consultation with their oncologist.

Potential Synergy with Chemotherapy, Radiation, and Immunotherapy

For most cancer patients, chemotherapy, radiation, and immunotherapy remain the cornerstones of standard care, and rightly so. These treatments save lives. The six-agent protocol is not designed to replace them. It is designed to make them work better and easier to tolerate.

The reasoning is straightforward. Chemotherapy and radiation kill cancer cells, but they depend on a functioning immune system to finish the job. Immunotherapy, particularly the checkpoint inhibitors that block PD-1, PD-L1, and CTLA-4, releases the brakes on T cells, but only works if T cells are present in the tumor, primed to recognize it, and not exhausted by the time they arrive. Many tumors fail to respond because they are immunologically cold, meaning T cells never infiltrate them in the first place. Others respond initially and then relapse as exhaustion sets in. When chemotherapy, radiation, and immunotherapy damage or fail to engage the immune system, they undermine the very mechanism that turns a good response into a lasting one. Each agent in this protocol addresses a different part of that problem.

High-ozonide oil

HOO appears to make tumor cells more vulnerable to radiation while sparing healthy tissues, a selectivity rooted in the mitochondrial differences between cancer and normal cells. Cardiolipin in healthy mitochondria binds tightly to cytochrome c, forming a thick membrane that blocks oxidizing radicals. In cancer cells, where the Krebs cycle is suppressed, and cytochrome c binding is lost, the membrane thins by roughly 10 angstroms and becomes permeable to HOO’s lipophilic ozonides, which trigger intrinsic apoptosis. The Izzotti 2022 study showed this directly: when HOO was added after a 2 Gy radiation dose, lung cancer cell viability dropped to 7.6%, well below radiation alone, while normal keratinocytes treated with the same oil showed no measurable change. Across a four-year follow-up of 115 cancer patients receiving HOO alongside standard chemotherapy and radiation, full recovery or downstaging was documented in 80% of cases, with notable responses in radioresistant prostate adenocarcinoma and glioblastoma. A 2024 study in esophageal cancer separately confirmed that adding ozone to radiation produced significantly greater tumor shrinkage than radiation alone. Ozone therapy has also been used to reduce the side effects of pelvic radiation and ease the nerve pain that often follows chemotherapy.

With respect to immunotherapy, the rationale rests on converting cold tumors to hot tumors. Rossmann and colleagues showed that ozone-driven oxidative stress in rabbits with head-and-neck carcinomas induced a tumoricidal immune response that could be transferred to naïve animals via their leukocytes, a classic signature of cold-to-hot conversion that checkpoint inhibitors require. Clavo and colleagues showed that systemic ozone therapy significantly reduced severely hypoxic regions within tumors, and tumor hypoxia is one of the strongest drivers of PD-L1 upregulation, regulatory T cell expansion, and T cell exhaustion, all of which predict checkpoint inhibitor failure. The Izzotti 2022 study also found that HOO inhibited the macrophage oxidative burst and that a high-grade prostate specimen taken after HOO treatment showed a near-absence of tumor-associated macrophages, which would otherwise suppress checkpoint inhibitor activity. No randomized trial has yet tested HOO alongside a checkpoint inhibitor, but the mechanistic logic is consistent and biologically grounded.

Microdosed resveratrol-copper

R-Cu takes on what may be the most underappreciated problem in cancer treatment. Chemotherapy and radiation kill cancer cells in massive waves, and those dying cells release chromatin debris that damages healthy tissue, drives the inflammation that fuels recurrence, and switches off the immune cells that would otherwise clean up residual cancer. In a clinical trial in advanced stomach cancer, adding R-Cu to standard chemotherapy significantly reduced severe side effects such as hand-foot syndrome, diarrhea, and vomiting. In a separate trial in patients receiving high-dose chemotherapy for multiple myeloma, it cut the rate of severe mouth sores from 100% to 40%. By clearing chromatin debris at the moment of maximum cell death, R-Cu helps protect both the patient and the immune response that conventional treatment is meant to provoke. It also raises the possibility of taming tumors before treatment begins, conditioning them toward a less aggressive state in advance.

The same chromatin debris that damages healthy tissue during chemotherapy and radiation also directly upregulates the immune checkpoints that anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies are designed to block. Shabrish and colleagues showed in 2024 that cell-free chromatin particles released from dying cancer cells induced PD-1, CTLA-4, LAG-3, TIM-3, and NKG2A on human T cells, and that R-Cu inactivated those particles, shutting off the signal at its source. The Pilankar RESCU 004 study extended this to patients: oral R-Cu before surgery for advanced oral cancer significantly downregulated multiple immune checkpoints within the tumor, with the lowest dose proving optimal. Resveratrol, on its own, has also been shown to disrupt PD-L1 glycosylation and trap PD-L1 within cancer cells before it reaches the cell surface, making tumor cells more susceptible to T-cell killing. R-Cu is best understood not as a substitute for checkpoint inhibitors but as an upstream silencer of the very signal that drives checkpoint expression.

Alkalinization therapy

Alkalinization removes a global resistance mechanism that operates across all three modalities. In the acidic tumor microenvironment, weak-base cytotoxic drugs such as doxorubicin, vincristine, and paclitaxel are protonated in the extracellular space, blocking their entry into cancer cells. Acidity also activates proton-driven efflux pumps, including P-glycoprotein and MRP1, which pump the drug back out. Raising extracellular pH increases intracellular drug retention, weakens efflux, improves microvascular perfusion, and weakens the acid-driven survival signaling that helps cancer cells tolerate cytotoxic injury. Hamaguchi and colleagues reported in 2020 in advanced or recurrent pancreatic cancer that adding alkalinization therapy to chemotherapy was associated with meaningfully prolonged median survival compared with chemotherapy alone, and a 2024 retrospective analysis by Isowa and colleagues of 98 stage-4 pancreatic cancer patients receiving alkalinization alongside standard care found that those who maintained urine pH at or above 7.5 lived nearly four times longer than those with urine pH below 6.5, and twice as long as those in the intermediate range of 6.5 to 7.4.

In a radiation environment, the acidic and hypoxic tumor microenvironment limits reactive oxygen species formation and supports antioxidant defenses that neutralize radiation-induced damage. Alkalinization improves perfusion, increases oxygen delivery, raises ROS production, weakens DNA repair signaling, and amplifies radiation-induced tumor kill. With checkpoint inhibitors, the failure mode is even more direct. T cells in acidic pH cannot release granules, produce cytokines, or proliferate, so even a perfectly targeted PD-1 or CTLA-4 antibody has nothing to unleash. Pilon-Thomas and colleagues showed in their 2016 Cancer Research paper that neutralizing tumor acidity with oral bicarbonate significantly improved responses to anti-CTLA-4 and anti-PD-1 antibodies, as well as to adoptive T cell therapy, in mouse models of melanoma and pancreatic cancer, an effect mediated by restored T cell metabolism and infiltration. Worsley and colleagues reviewed the broader literature in 2022, framing acidity as a unifying immune-escape mechanism whose reversal can rescue otherwise failed immunotherapy responses.

Beta-glucans

Beta-glucans help the immune system handle the wave of dying cancer cells induced by chemotherapy and radiation. Decades of Japanese research on PSK have shown that adding it to chemotherapy in patients with colon and stomach cancer reduces recurrence and improves survival. In one large analysis of patients with resected colon cancer, PSK reduced five-year mortality by 29%. Beta-glucans also help white blood cell counts recover more quickly after chemotherapy, potentially preserving dose intensity.

They also have what may be the deepest published evidence among the six agents for direct synergy with checkpoint inhibitors. Geller and colleagues showed in 2022 that yeast whole-glucan particle reprogrammed the innate immune system through trained immunity and that combining it with anti-PD-L1 produced significantly longer survival than either treatment alone in pancreatic cancer, one of the tumor types most resistant to checkpoint blockade. Hu and colleagues showed in 2023 that adding anti-PD-L1 to beta-glucan synergistically induced regression of melanoma tumors in mice, with tumor-infiltrating T cells showing markedly improved cytotoxic function. Wang and colleagues paired animal experiments with a small clinical cohort of patients whose cancers had progressed on prior anti-PD-1 or anti-PD-L1 therapy, finding that adding beta-glucan was associated with improved progression-free survival, suggesting beta-glucans can partially reverse acquired resistance to checkpoint inhibitors.

Thymosin alpha-1

Thymosin alpha-1 rescues immune cells depleted by chemotherapy and radiation. A pooled analysis of 27 trials in lung cancer found that patients who received it alongside chemotherapy had higher response rates, longer survival, and fewer treatment-related side effects. In patients receiving combined chemotherapy and radiation for lung cancer, it also reduced the risk of radiation-induced lung inflammation.

Of the six agents, thymosin alpha-1 has the most mature clinical evidence supporting combination with checkpoint inhibitors. Costantini and colleagues laid out the mechanistic case in 2019: thymosin alpha-1 induces MHC class I on tumor cells, drives interferon-gamma production, matures dendritic cells, and broadens the T cell repertoire, collectively turning cold tumors into hot tumors capable of responding to checkpoint blockade. King and Tuthill showed in a melanoma model that combining thymosin alpha-1 with an anti-PD-1 antibody produced significantly fewer metastases than either alone. The most striking clinical signal comes from Danielli and colleagues, who reported in 2018 that metastatic melanoma patients who received thymosin alpha-1 first and then sequential ipilimumab had a median overall survival of 38.4 months, compared with 8 months for ipilimumab alone in the same setting, with a five-year overall survival of 41% versus 13%.

Thymosin alpha-1 also addresses one of the most troubling problems with checkpoint inhibitors, the immune-related colitis that disqualifies many patients from continued therapy. Renga and colleagues showed that thymosin alpha-1 prevents anti-CTLA-4-induced colitis through a tolerogenic pathway in the gut while improving the antitumor effector-to-regulatory T cell ratio inside the tumor, separating the toxicity from the efficacy in a way that is uncommon among adjunct strategies. A 2025 prospective analysis by Zhang and colleagues found that adding thymosin alpha-1 to chemoradiation followed by consolidative anti-PD-L1, in unresectable lung cancer, was associated with improved progression-free and overall survival, accelerated lymphocyte recovery, and reduced radiation-induced pneumonitis, which often forces patients off immunotherapy.

Low-dose naltrexone

LDN appears to make chemotherapy work harder while easing some of its toughest side effects. Animal studies have shown that combining LDN with cisplatin produces greater tumor inhibition than cisplatin alone. In clinical practice, LDN is widely used to reduce the nerve pain, fatigue, and mental fog that often follow chemotherapy.

The case for combining LDN with checkpoint inhibitors is the most preliminary of the six and rests on mechanism rather than direct clinical evidence. Liu and colleagues showed that the low-dose, intermittent schedule of naltrexone produces a different gene expression pattern from continuous, full-dose use, selectively activating immunomodulatory and pro-apoptotic pathways. Cant and colleagues found that naltrexone suppresses interleukin-6 production by monocytes and dendritic cells, and elevated interleukin-6 is one of the better-characterized drivers of resistance to checkpoint inhibitors and of severe immune-related side effects. A 2025 study using a closely related opioid antagonist showed that low-dose treatment reduced PD-1, LAG-3, and TIM-3 on exhausted CD8 T cells while increasing their production of interferon-gamma, tumor necrosis factor-alpha, and granzyme B, addressing exactly the exhaustion phenotype that defeats checkpoint blockade in many patients. No randomized trial of LDN with a checkpoint inhibitor has been published, so its placement here is hypothesis-generating; however, the mechanistic alignment with the failure modes of checkpoint inhibitors is consistent.

Taken together, these six agents do not interfere with conventional cancer treatment. They strengthen it. They help patients tolerate it better. And they extend their reach by keeping the immune system capable of finishing what chemotherapy, radiation, and immunotherapy begin.

The hierarchy of supporting evidence varies. The strongest published synergy data are for thymosin alpha-1, beta-glucans, and alkalinization. R-Cu and HOO are mechanistically grounded with more limited clinical data, and the case for LDN is chiefly mechanistic. None of these combinations has been validated in a randomized trial against modern checkpoint inhibitors, but each agent corrects a defined biological deficit that chemotherapy, radiation, and checkpoint blockade alone do not address.

Cancer Stem Cells: How the Six-Agent Protocol May Reach the Cells That Drive Recurrence

Why cancer stem cells are the cells that matter most

When most people picture cancer, they imagine a lump of identical cells growing out of control. The reality is a little different. Inside almost every tumor lives a small minority of cells, often just a few percent, that behave very differently from the rest. These are the cancer stem cells, and they are the ones that decide whether you stay in remission or relapse.

Like normal stem cells in your bone marrow and gut, cancer stem cells can self-renew indefinitely and produce all the different cell types in a tumor. They are the seeds of the disease. The bulk of what shows up on a scan is mostly their offspring. Kill the offspring, and the tumor shrinks. Leave the seeds, and it grows back.

What makes them so hard to eliminate is a layered set of defenses ordinary cancer cells do not have. They install pumps in their membranes that push chemotherapy back out before it can work. They spend long stretches in a sleeping state, so drugs designed to hit rapidly dividing cells pass right over them. They repair their own DNA more efficiently, blunting the damage radiation is supposed to cause. They carry an enzyme called ALDH that neutralizes oxidative stress and detoxifies certain chemotherapy drugs from the inside. And they keep their internal levels of reactive oxygen species unusually low, the same trick that makes them resistant to radiation.

They also do not live alone. Cancer stem cells are sustained by their surroundings, which we call the niche, built from low-oxygen pockets, acidic fluid, immune cells turned toward the tumor, and a constant rain of debris from dying neighboring cells. Every part of that environment sends signals that keep the stem cells alive, quiet, and ready to repopulate the tumor once treatment stops.

This is why a treatment that shrinks a tumor by ninety percent can still be followed, months or years later, by recurrence. The visible disease responded; the seeds did not. Any serious anticancer strategy has to do more than kill cancer cells in bulk. It has to dismantle the conditions that keep the stem cells alive, and, where possible, attack the stem cells themselves. Each of the six agents in this protocol contributes to that effort in a different way.

High-ozonide oil

Of all the agents in this protocol, HOO is the one whose researchers explicitly built it with cancer stem cells in mind. The Izzotti paper from 2022 frames the problem in the same terms used at the start of this section: relapses stem from cancer stem cells, those cells survive chemotherapy and radiation by maintaining unusually high levels of internal antioxidants, and any treatment hoping to prevent recurrence has to break through that antioxidant shield. HOO was designed to do exactly that.

The evidence that it actually does so comes in three layers. The first is biochemical. When the Izzotti team measured the elemental composition of cancer cells before and after HOO, the carbon-to-oxygen ratio fell from 4.3 to 1.5. In plain terms, the antioxidant-rich interior that defines the cancer stem cell phenotype was overwhelmed and replaced by an oxidized one. The second is systemic. In their 115-patient cohort, blood antioxidant levels were high before treatment, just the imbalance you would expect if the body was supporting a cancer stem cell population, and HOO brought those levels back to normal. In one pediatric brain cancer patient, the same effect was measurable in the cerebrospinal fluid, showing that HOO reaches the central nervous system. The third layer is functional. After a 2 Gy dose of radiation, the cells that should have survived because of their antioxidant defenses, the stem cell fraction, did not survive when HOO was added. Cell viability dropped to 7.6%, well below what radiation alone achieved, while normal skin cells exposed to the same oil showed no harm.

The honest caveat is that the Izzotti team did not directly stain for standard cancer stem cell markers such as CD44, CD133, or ALDH, so we cannot say with certainty that the cells dying in their experiments were stem cells by those formal definitions. What we can say is that HOO collapses the redox environment that cancer stem cells specifically depend on, depletes the systemic antioxidant reservoir that feeds them, and kills the radiation-resistant fraction that, operationally, behaves like cancer stem cells, all while sparing healthy cells whose mitochondria are intact. Among the six agents, this is one of the more substantial mechanistic cases for direct cancer stem cell targeting.

Microdosed resveratrol-copper

R-Cu acts on cancer stem cells through two distinct routes. Resveratrol on its own has been shown in laboratory and animal models of breast, pancreatic, brain, head and neck, and colon cancer to shrink the cancer stem cell population. It does this by switching off the master genes that keep cells in a stem-like state, names like NANOG, OCT4, and SOX2, and by blocking the developmental signaling pathways called Wnt, Hedgehog, and Notch that cancer stem cells rely on. The honest caveat is that most of these studies used much higher concentrations than you can achieve orally, which is part of why oral resveratrol alone has been disappointing as a cancer therapy.

The second route is what makes the copper combination important. Work from the Tata Memorial Centre in Mumbai has shown that when dying cancer cells release fragments of their DNA into surrounding tissue, those fragments are not inert debris. They drift into healthy cells, integrate into their DNA, cause damage, ignite inflammation, and, most strikingly, can convert ordinary cells into cancer stem cells. Chromatin debris released during chemotherapy and natural tumor turnover is itself a source of new cancer stem cells. Trace amounts of copper, paired with low-dose resveratrol, generate a precisely targeted oxidative reaction that breaks down this debris before it can cause damage. A small but striking 2025 study in glioblastoma patients receiving R-Cu before surgery found a roughly 56% reduction in three cancer stem cell markers in the resected tumor. This is the strongest direct human evidence among the six agents that one of them actually reaches the cancer stem cell compartment in patients.

Alkalinization therapy

The fluid around tumor cells is acidic, often a full pH unit lower than nearby healthy tissue. That acidity does more than impair the immune system, which is its role in the main body of this document. It also actively converts ordinary cancer cells into cancer stem cells. Studies in glioma, melanoma, pancreatic, prostate, and bile duct cancers have shown that simply exposing cancer cells to acidic conditions turns on the same stem cell genes mentioned above and produces cells that form tumors more aggressively in animals. The acidic environment also drives a survival process called autophagy, in which the cell eats parts of itself to stay alive under stress, and this autophagy preferentially protects the stem cell population.

Reversing the acidity is therefore not just about helping the immune system. In animal models, oral sodium bicarbonate and similar buffering strategies reduce metastasis, which is itself seeded by cancer stem cells. In a clinical study of pancreatic cancer patients, those who maintained a urine pH above 7.0 with bicarbonate and dietary changes lived markedly longer than those whose urine remained acidic. No clinical trial has yet measured the cancer stem cell population directly before and after alkalinization, so the case here is mechanistically very strong but not yet proven in patients. What is clear is that you cannot ask the immune system to clean up cancer stem cells in an environment that keeps generating more of them.

Beta-glucans

Beta-glucans contribute to cancer stem cell control in two ways. The first is direct. A specific beta-glucan called PSP, derived from the same Trametes versicolor mushroom as PSK, has been shown in laboratory and animal studies to reduce cancer stem cell markers in prostate cancer and to prevent prostate tumors from forming at all in genetically engineered mice. A related Trametes-derived compound has shown similar effects in colon cancer stem cells.

The second way may be more important. Cancer stem cells often display a feature called low MHC class I, a kind of molecular flag that normally signals the immune system what is inside a cell. With the flag down, T cells cannot recognize the stem cells. But natural killer cells, a different arm of the immune system, are specifically built to attack cells that have lowered their flags. Beta-glucans are powerful activators of natural killer cells, and several studies have shown that those cells preferentially target cancer stem cells. In Japanese clinical trials of stomach cancer, the survival benefit of PSK was largest in exactly those tumors with low MHC class I, the pattern you would expect if the benefit were mediated through NK cell killing of stem cells. Beta-glucans also help convert tumor-supporting macrophages back into tumor-fighting ones, which removes another piece of the cancer stem cell niche.

Thymosin alpha-1

The direct evidence for thymosin alpha-1 acting on cancer stem cells comes from a single but useful study in colon cancer, which showed that thymosin alpha-1 increases the expression of a molecule called CD1d on tumor cells. CD1d acts as a recognition signal for a specialized class of immune cells called invariant natural killer T cells, and once that signal is restored, those cells preferentially kill cancer stem cells.

Beyond that one study, thymosin alpha-1’s role here is mechanistic and depends on its broader work as the conductor of the adaptive immune system. By maturing dendritic cells, it helps the immune system see the unique mutations that distinguish each cancer, including those carried by cancer stem cells. By converting tumor-protecting macrophages back into tumor-fighting ones, it dismantles a key piece of the cancer stem cell niche. By restoring MHC class I on tumor cells, it gives T cells back their ability to recognize cells that had been hiding from them. Clinical studies in liver cancer and metastatic melanoma have shown survival benefits when thymosin alpha-1 is added to other treatments, consistent with this kind of broad immune restoration, even though those studies did not measure cancer stem cells directly.

Low-dose naltrexone

The case for LDN reaching cancer stem cells rests on its effect on the opioid growth factor axis, which researchers at Penn State have studied for more than two decades. By briefly blocking opioid receptors at night, LDN triggers a compensatory rise in the body’s own opioid growth factor and beta-endorphin during the day. The elevated growth factor activates two cellular brakes, p16 and p21, that slow cell division, and these same brakes are central to how stem cells decide whether to remain quiescent or expand.

A study in cervical cancer showed that LDN reduces colony formation, reverses the cellular shape-shifting that cancer stem cells use to invade and metastasize, and shuts down the same internal pathways, PI3K, AKT, and mTOR, that cancer stem cells depend on. LDN also reduces interleukin-6 production by immune cells, and interleukin-6 is one of the main inflammatory signals that sustain cancer stem cells after chemotherapy and radiation. There are no clinical trials yet that have measured cancer stem cells directly in patients on LDN, so this is the most preliminary of the six rationales, but the mechanisms align well with what cancer stem cells need to survive treatment.

Putting it together

A pattern emerges across these six agents that is more than coincidence. Each addresses a different vulnerability in cancer stem cells, and together they triangulate on the problem from several directions. HOO and R-Cu deliver the kind of oxidative and chromatin-clearing stress that cancer stem cells, with their unusual antioxidant defenses, cannot easily tolerate. Alkalinization removes the acidic conditions that perpetuate the generation of new cancer stem cells from ordinary tumor cells. Beta-glucans and thymosin alpha-1 redirect the innate and adaptive immune systems toward exactly the cell phenotype, MHC class I-low, that conventional therapies most reliably miss. And LDN applies a quiescence brake while damping the inflammation that otherwise rescues stem cells after every cytotoxic insult.

No single agent in this protocol has been proven in randomized trials to eliminate cancer stem cells in patients, and I want to be clear-eyed about that. The honest claim is more measured. Each one acts at a documented point in cancer stem cell biology where chemotherapy, radiation, and immunotherapy alone do not, and their mechanisms do not overlap, which is why using them in combination is preferable to picking one. The protocol is best understood not as six different attempts to kill the same cell, but as a coordinated effort to dismantle the conditions under which the cancer stem cell ordinarily survives the treatments meant to cure the patient.

References

1. Agarwal A, Khandelwal A, Pal K, Khare NK, Jadhav V, Gurjar M, Punatar S, Gokarn A, Bonda A, Nayak L, Kannan S, Gota V, Khattry N, Mittra I. A novel pro-oxidant combination of resveratrol and copper reduces transplant related toxicities in patients receiving high dose melphalan for multiple myeloma (RESCU 001). PLoS One. 2022;17(2):e0262212.
2. Ahmadpour ST, Maheo K, Servais S, Brisson L, Dumas JF. Cardiolipin, the mitochondrial signature lipid: implication in cancer. Int J Mol Sci. 2020;21(21):8031.
3. Albeituni SH, Ding C, Liu M, Hu X, Luo F, Kloecker G, Bousamra M 2nd, Zhang HG, Yan J. Yeast-derived particulate beta-glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation to APC in cancer. J Immunol. 2016;196(5):2167-2180.
4. Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, Hagino T, Perez-Cunningham J, Sckisel GD, Urayama S, et al. NK cells preferentially target tumor cells with a cancer stem cell phenotype. J Immunol. 2015;195(8):4010-4019.
5. Andreucci E, Peppicelli S, Ruzzolini J, Bianchini F, Biagioni A, Papucci L, Magnelli L, Mazzanti B, Stecca B, Calorini L. The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells. J Mol Med (Berl). 2020;98(10):1431-1446.
6. Bandiwadekar C, Naorem LD, Moiyadi AV, et al. Attenuation of malignant phenotype of glioblastoma following a short course of the pro-oxidant combination of resveratrol and copper. BJC Reports. 2025;3(1):68.
7. Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82:103-126.
8. Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, Friedman GK, Hjelmeland AB. Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 2021;11(2):665-683.
9. Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, Huber V, Parmiani G, Generoso L, Santinami M, Borghi M, Fais S, Bellone M, Rivoltini L. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72(11):2746-2756.
10. Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular Toll-like receptors. Front Immunol. 2017;8:809.
11. Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, Sher L, Dooley S, French SW, Mishra L, Petrovic L, et al. Reciprocal regulation by TLR4 and TGF-beta in tumor-initiating stem-like cells. J Clin Invest. 2013;123(7):2832-2849.
12. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
13. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer. 2008;7:5.
14. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res. 2007;67(21):10511-10518.
15. Cilibrasi C, Riva G, Romano G, Cadamuro M, Bazzoni R, Butta V, Paoletta L, Dalpra L, Strazzabosco M, Lavitrano M, et al. Resveratrol impairs glioma stem cells proliferation and motility by modulating the Wnt signaling pathway. PLoS One. 2017;12(1):e0169854.
16. Clavo B, Pérez JL, López L, Suárez G, Lloret M, Rodríguez V, Macías D, Santana M, Hernández MA, Martín-Oliva R, Robaina F. Ozone therapy for tumor oxygenation: a pilot study. Evid Based Complement Alternat Med. 2004;1(1):93-98.
17. Clavo B, Rodríguez-Esparragón F, Rodríguez-Abreu D, Martínez-Sánchez G, Llontop P, Aguiar-Bujanda D, Fernández-Pérez L, Santana-Rodríguez N. Modulation of oxidative stress by ozone therapy in the prevention and treatment of chemotherapy-induced toxicity: review and prospects. Antioxidants (Basel). 2019;8(12):588.
18. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012;109(8):2784-2789.
19. Costantini C, Bellet MM, Pariano M, Renga G, Stincardini C, Goldstein AL, Garaci E, Romani L. A reappraisal of thymosin alpha1 in cancer therapy. Front Oncol. 2019;9:873.
20. Danielli R, Cisternino F, Giannarelli D, Calabrò L, Camerini R, Savelli V, Bova G, Dragonetti R, Di Giacomo AM, Altomonte M, Maio M. Long-term follow up of metastatic melanoma patients treated with thymosin alpha-1: investigating immune checkpoints synergy. Expert Opin Biol Ther. 2018;18(sup1):77-83.
21. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458(7239):780-783.
22. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood). 2011;236(7):883-895.
23. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood). 2011;236(9):1036-1050.
24. Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, Johnson J, Gatenby RA, Gillies RJ. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73(5):1524-1535.
25. Filatova A, Seidel S, Bogurcu N, Graf S, Garvalov BK, Acker T. Acidosis acts through HSP90 in a PHD/VHL-independent manner to promote HIF function and stem cell maintenance in glioma. Cancer Res. 2016;76(19):5845-5856.
26. Fu Y, Chang H, Peng X, Bai Q, Yi L, Zhou Y, Zhu J, Mi M. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt and beta-catenin signaling pathway. PLoS One. 2014;9(7):e102535.
27. Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337.
28. Geller AE, Shrestha R, Woeste MR, Guo H, Hu X, Ding C, Andreeva K, Chariker JH, Zhou M, Tieri D, Watson CT, Mitchell RA, Zhang HG, Li Y, Martin RCG 2nd, Rouchka EC, Yan J. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nat Commun. 2022;13(1):759.
29. Giuliani C, Napolitano G, Mastino A, Di Vincenzo S, D’Agostini C, Grelli S, Bucci I, Singer DS, Kohn LD, Monaco F, et al. Thymosin alpha-1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30(3):778-786.
30. Guo CL, Mei JD, Jia YL, Gan FY, Tang YD, Liu CW, Zeng Z, Yang ZY, Deng SY, Sun X, Liu LX. Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis. Chin Med J (Engl). 2021;134(22):2700-2709.
31. Guo J, Cheng B, Gong M, Sun X, Zhang H, Ma J. Ozone enhances the efficacy of radiation therapy in esophageal cancer. J Radiat Res. 2024;65(4):467-473.
32. Hamaguchi R, Isowa M, Narui R, Morikawa H, Wada H. Clinical review of alkalization therapy in cancer treatment. Front Oncol. 2022;12:1003588.
33. Hamaguchi R, Narui R, Wada H. Effects of alkalization therapy on chemotherapy outcomes in metastatic or recurrent pancreatic cancer. Anticancer Res. 2020;40(2):873-880.
34. He YY, Liu S, Newburg DS. Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth. Biomed Pharmacother. 2021;144:112339.
35. Hirahara N, Edamatsu T, Fujieda A, Fujioka M, Wada T, Tajima Y. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Exp Ther Med. 2012;3(1):2-6.
36. Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, McLendon R, Lindner D, Sloan A, Rich JN. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011;18(5):829-840.
37. Hu X, Shui Y, Hirano H, Kusano K, Guo WZ, Fujino M, Li XK. PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model. Cancer Immunol Immunother. 2023;72(3):719-731.
38. Isowa M, Hamaguchi R, Narui R, Morikawa H, Okamoto T, Wada H. Potential of alkalization therapy for the management of metastatic pancreatic cancer: a retrospective study. Cancers (Basel). 2024;16(1):61.
39. Izzotti A, Fracchia E, Rosano C, Comite A, Belgioia L, Sciacca S, Khalid Z, Congiu M, Colarossi C, Blanco G, Santoro A, Chiara M, Pulliero A. Efficacy of high-ozonide oil in prevention of cancer relapses mechanisms and clinical evidence. Cancers (Basel). 2022;14(5):1174.
40. Kalafati L, Kourtzelis I, Schulte-Schrepping J, Li X, Hatzioannou A, Grinenko T, Hagag E, Sinha A, Has C, Dietz S, de Jesus Domingues AM, Nati M, Sormendi S, Neuwirth A, Chatzigeorgiou A, Ziogas A, Lesche M, Dahl A, Henry I, Subramanian P, Wielockx B, Murray P, Mirtschink P, Chung KJ, Schultze JL, Netea MG, Hajishengallis G, Verginis P, Mitroulis I, Chavakis T. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183(3):771-785.e12.
41. King RS, Tuthill C. Evaluation of thymosin α1 in nonclinical models of the immune-suppressing indications melanoma and sepsis. Expert Opin Biol Ther. 2015;15(Suppl 1):S41-S49.
42. Kirolikar S, Prasannan P, Raghuram GV, Pancholi N, Saha T, Tidke P, Chaudhari P, Shaikh A, Rane B, Pandey R, et al. Prevention of radiation-induced bystander effects by agents that inactivate cell-free chromatin released from irradiated dying cells. Cell Death Dis. 2018;9(12):1142.
43. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860-875.
44. Linye H, Zijing X, Wei P, Chao H, Chuan L, Tianfu W. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: a propensity score matching analysis. Medicine (Baltimore). 2021;100(20):e25749.
45. Liu F, Qiu B, Xi Y, Luo Y, Luo Q, Wu Y, Chen N, Zhou R, Guo J, Wu Q, Xiong M, Liu H. Efficacy of thymosin α1 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: a phase 2 clinical trial (GASTO-1043). Int J Radiat Oncol Biol Phys. 2022;114(3):433-443.
46. Liu M, Luo F, Ding C, Albeituni S, Hu X, Ma Y, Cai Y, McNally L, Sanders MA, Jain D, et al. Dectin-1 activation by a natural product beta-glucan converts immunosuppressive macrophages into an M1-like phenotype. J Immunol. 2015;195(10):5055-5065.
47. Liu N, Ma M, Qu N, Wang R, Chen H, Hu F, Gao S, Shan F. Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo. Int Immunopharmacol. 2020;86:106718.
48. Liu WM, Dalgleish AG. Naltrexone at low doses (LDN) and its relevance to cancer therapy. Expert Rev Anticancer Ther. 2022;22(3):269-274.
49. Liu WM, Scott KA, Dennis JL, Kaminska E, Levett AJ, Dalgleish AG. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy. Int J Oncol. 2016;49(2):793-802.
50. Luk SU, Lee TK, Liu J, Lee DT, Chiu YT, Ma S, Ng IO, Wong YC, Chan FL, Ling MT. Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One. 2011;6(5):e19804.
51. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, Asahina K, Govindarajan S, Ray R, Ou JH, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A. 2009;106(5):1548-1553.
52. Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010;28(10):1780-1787.
53. Min X, Ma Y, Lv M, Li X, Lv R, Zhao X, Leng Y. Exploring the possible mechanism of low-dose naloxone exposure improving the immune microenvironment of gastric cancer tumors. Front Immunol. 2025;16:1524930.
54. Mittra I, Khare NK, Raghuram GV, Chaubal R, Khambatti F, Gupta D, Gaikwad A, Prasannan P, Singh A, Iyer A, Singh A, Upadhyay P, Nair NK, Mishra PK, Dutt A. Circulating nucleic acids damage DNA of healthy cells by integrating into their genomes. J Biosci. 2015;40(1):91-111.
55. Mittra I, Pal K, Pancholi N, Shaikh A, Rane B, Tidke P, Kirolikar S, Khare NK, Agrawal K, Nagare H, Nair NK. Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin. Ann Oncol. 2017;28(9):2119-2127.
56. Mittra I, Samant U, Sharma S, Raghuram GV, Saha T, Tidke P, Pancholi N, Gupta D, Prasannan P, Gaikwad A, et al. Cell-free chromatin from dying cancer cells integrate into genomes of bystander healthy cells to induce DNA damage and inflammation. Cell Death Discov. 2017;3:17015.
57. Mittra I. Exploiting the damaging effects of ROS for therapeutic use by deactivating cell-free chromatin: the alchemy of resveratrol and copper. Front Pharmacol. 2024;15:1345786.
58. Ni C, Wu P, Wu X, Zhang T, Zhang T, Wang Z, Wu S, Qiu F, Huang J. Thymosin alpha-1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression. Cancer Lett. 2015;356(2 Pt B):579-588.
59. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007;56(6):905-911.
60. Ostwal V, Ramaswamy A, Bhargava P, Srinivas S, Mandavkar S, Chaugule D, Peelay Z, Baheti A, Tandel H, Jadhav VK, Shinde S, Jadhav S, Gota V, Mittra I. A pro-oxidant combination of resveratrol and copper reduces chemotherapy-related non-haematological toxicities in advanced gastric cancer: results of a prospective open label phase II single-arm study (RESCU III study). Med Oncol. 2023;40(1):17.
61. Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, Xing F, Fukuda K, Hirota S, Sugai T, et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat. 2011;130(2):387-398.
62. Pilankar A, Singhavi H, Raghuram GV, Siddiqui S, Khare NK, Jadhav V, Tandel H, Pal K, Bhattacharjee A, Chaturvedi P, Mittra I. A pro-oxidant combination of resveratrol and copper down-regulates hallmarks of cancer and immune checkpoints in patients with advanced oral cancer: results of an exploratory study (RESCU 004). Front Oncol. 2022;12:1000957.
63. Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 2016;76(6):1381-1390.
64. Raghuram GV, Tripathy BK, Avadhani K, Shabrish S, Khare NK, Pal K, Shaikh A, Mittra I. Cell-free chromatin particles released from dying cells inflict mitochondrial damage and ROS production in living cells. Cell Death Discov. 2024;10(1):30.
65. Renga G, Bellet MM, Pariano M, Gargaro M, Stincardini C, D’Onofrio F, Mosci P, Brancorsini S, Bartoli A, Goldstein AL, Garaci E, Romani L, Costantini C. Thymosin α1 protects from CTLA-4 intestinal immunopathology. Life Sci Alliance. 2020;3(10):e202000662.
66. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009;69(6):2260-2268.
67. Rolver MG, Camacho-Roda J, Dai Y, Flinck M, Ialchina R, Hindkaer J, Dyhr RT, Bodilsen AN, Prasad NS, Baldan J, Yao J, Sandelin A, Arnes L, Pedersen SF. Tumor microenvironment acidosis favors pancreatic cancer stem cell properties and in vivo metastasis. iScience. 2025;28(3):111956.
68. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, et al. Thymosin alpha-1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232-4239.
69. Rossmann A, Mandic R, Heinis J, Höffken H, Küssner O, Kinscherf R, Weihe E, Bette M. Intraperitoneal oxidative stress in rabbits with papillomavirus-associated head and neck cancer induces tumoricidal immune response that is adoptively transferable. Clin Cancer Res. 2014;20(16):4289-4301.
70. Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y; Meta-Analysis Group of the Japanese Society for Cancer of the Colon Rectum. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother. 2006;55(4):404-411.
71. Shabrish S, et al. Induction of cancer stem cells from mouse fibroblasts. Sci Rep. 2025;15(1):25489.
72. Shabrish S, Pal K, Khare NK, Satsangi D, Pilankar A, Jadhav V, Shinde S, Raphael N, Sriram G, Lopes R, Raghuram GV, Tandel H, Mittra I. Cell-free chromatin particles released from dying cancer cells activate immune checkpoints in human lymphocytes: implications for cancer therapy. Front Immunol. 2024;14:1331491.
73. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, Srivastava RK. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One. 2011;6(1):e16530.
74. Shen YA, Lin CH, Chi WH, Wang CY, Hsieh YT, Wei YH, Chen YJ. Resveratrol impedes the stemness, epithelial-mesenchymal transition, and metabolic reprogramming of cancer stem cells in nasopharyngeal carcinoma through p53 activation. Evid Based Complement Alternat Med. 2013;2013:590393.
75. Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN, La Rocca R, et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol. 2013;190(5):2381-2390.
76. Thongchot S, Vidoni C, Reano S, Loilome W, Yongvanit P, Namwat N, Filigheddu N, Isidoro C. The upregulation of OCT4 in acidic extracellular pH is associated with gemcitabine resistance in cholangiocarcinoma cell lines. J Gastrointest Cancer. 2020;51(2):540-546.
77. Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, Bosch-Barrera J, Encinar JA, Menendez JA. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging (Albany NY). 2020;12(1):8-34.
78. Wang M, Bai Y, Pei J, Li D, Pu X, Zhu W, Xia L, Qi C, Jiang H, Ning Y. β-glucan combined with PD-1/PD-L1 checkpoint blockade for immunotherapy in patients with advanced cancer. Front Pharmacol. 2022;13:887457.
79. Ward C, Meehan J, Gray ME, Murray AF, Argyle DJ, Kunkler IH, Langdon SP. The impact of tumour pH on cancer progression: strategies for clinical intervention. Explor Target Antitumor Ther. 2020;1(2):71-100.
80. Wei YT, Wang XR, Yan C, Huang F, Zhang Y, Liu X, Wen ZF, Sun XT, Zhang Y, Chen YQ, Gao R, Pan N, Wang LX. Thymosin α-1 reverses M2 polarization of tumor-associated macrophages during efferocytosis. Cancer Res. 2022;82(10):1991-2002.
81. Wojtkowiak JW, Rothberg JM, Kumar V, Schramm KJ, Haller E, Proemsey JB, Lloyd MC, Sloane BF, Gillies RJ. Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res. 2012;72(16):3938-3947.
82. Worsley CM, Veale RB, Mayne ES. The acidic tumour microenvironment: manipulating the immune response to elicit escape. Hum Immunol. 2022;83(5):399-408.
83. Yang YP, Chang YL, Huang PI, Chiou GY, Tseng LM, Chiou SH, Chen MH, Chen MT, Shih YH, Chang CH, et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol. 2012;227(3):976-993.
84. Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: a review. World J Gastroenterol. 2014;20(9):2218-2223.
85. Zeng FL, Xiao Z, Wang CQ, Jiang Y, Shan JL, Hu SS, Huang XR, Tang YH, Yao XS, Zhang T, Zeng XT, Feng JH, Xiao X. Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: a systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. Int Immunopharmacol. 2019;75:105747.
86. Zhang HT, Liu FJ, Wang DQ, Xiong YX, Zhao YY, He WZ, Zhang PX, Zheng SY, Xia B, Situ Y, Wang MR, Liu QW, Hu Y, Xia LP, Qiu B, Liu H. A preliminary analysis of integrating thymosin α1 into concurrent chemoradiotherapy and consolidative immunotherapy in unresectable locally advanced non-small cell lung cancer. Transl Lung Cancer Res. 2025;14(7):2710-2722.
87. Zhou D, Shao L, Spitz DR. Reactive oxygen species in normal and tumor stem cells. Adv Cancer Res. 2014;122:1-67.

Disclaimer

This information is intended for educational discussion between physicians and informed patients and does not constitute medical advice. The six-agent combination described here has not been evaluated in a formal clinical trial, and no claim of efficacy is made. All treatment decisions should be made in consultation with the patient’s oncologist.